The role of hyperbaric oxygen treatment in the management of spondylodiscitis
Diving and Hyperbaric Medicine Journal · 2024
DOI: 10.28920/dhm54.3.162-167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diving and Hyperbaric Medicine Journal, 2024. Verfasst von Kübra Canarslan Demir und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Underwater and Hyperbaric Medicine, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkey. Hauptthemen laut MEDLINE: Hyperbaric Oxygenation, Discitis, C-Reactive Protein, Anti-Bacterial Agents. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
This study analysed treatment outcomes in a patient cohort diagnosed with spondylodiscitis, who received adjunct hyperbaric oxygen treatment (HBOT) in addition to antibiotic therapy at our clinic. Important considerations included the timing of HBOT initiation on treatment success, and recurrence rates.
Methods
We retrospectively reviewed the records of all patients diagnosed with spondylodiscitis who received HBOT at the Underwater and Hyperbaric Medicine Clinic in Gulhane Training and Research Hospital, between 1 November 2016 and 25 October 2022. The patients received HBOT at 243.2 kPa for a total of 120 minutes per session, once daily for five days a week for a total of 30 sessions.
Results
Twenty-five patients with spondylodiscitis were evaluated before and after combination HBOT and targeted antibiotic treatment. After treatment, patients had lower median (range) visual analogue pain scores (8 [4–10] vs 3 [0–7], P < 0.001) and C-reactive protein (22.3 [4.3–79.9] mg·L⁻¹ vs 6.8 [0.1–96.0] mg·L⁻¹, P = 0.002) and lower mean (standard deviation) white blood cell counts (8.8 [3.5] x 10⁹·L⁻¹ vs 6.1 [1.6] x 109·L⁻¹, P = 0.002). When patients were examined (median) 48 months (2–156 months) after the completion of treatment, there were no persistent cases of spondylodiscitis.
Conclusions
Combination HBOT with targeted antibiotic therapy effectively managed our cohort of patients diagnosed with spondylodiscitis. Hyperbaric oxygen treatment was safe, with no complications experienced. Moreover, HBOT may have helped to eliminate persistence and recurrence of symptoms with long term follow-up. A randomised controlled study with a larger number of patients is needed for more definitive conclusions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Underwater and Hyperbaric Medicine, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkey.
- Corresponding author: Dr Kübra Canarslan Demir, SBÜ-Gülhane Eğitim ve Araştırma Hastanesi, Sualtı Hekimliği ve Hiperbarik Tıp Kliniği, Etlik/Ankara, Turkey drcanarslan@hotmail.com.
- Department of Public Health, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkey.
Zitieren
APA
Canarslan Demir, K., Turgut, B., Sariyerli Dursun, G. B., Konyalioğlu, F. S., & Zaman, T. (2024). The role of hyperbaric oxygen treatment in the management of spondylodiscitis. Diving and Hyperbaric Medicine Journal. https://doi.org/10.28920/dhm54.3.162-167
Vancouver
Canarslan Demir K, Turgut B, Sariyerli Dursun GB, Konyalioğlu FS, Zaman T. The role of hyperbaric oxygen treatment in the management of spondylodiscitis. Diving and Hyperbaric Medicine Journal. 2024. doi:10.28920/dhm54.3.162-167
BibTeX
@article{CanarslanDemir2024,
author = {Canarslan Demir, Kübra and Turgut, Burak and Sariyerli Dursun, Gözde B and Konyalioğlu, Fatma S and Zaman, Taylan},
title = {The role of hyperbaric oxygen treatment in the management of spondylodiscitis},
journal = {Diving and Hyperbaric Medicine Journal},
year = {2024},
doi = {10.28920/dhm54.3.162-167}
}
EUVIMED